文献速递肝病

抑制ATG3通过增强线粒体功能改善肝脂肪变性

Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function.
PubMed 文献 · J Hepatol · 2021-09-21

该研究在小鼠与NAFLD患者肝脏中发现ATG3表达升高,通过敲低ATG3可减轻p63及饮食诱导的脂肪变性,机制为降低JNK1、上调SIRT1与CPT1a以增强线粒体功能且不依赖自噬。

要点

  • NAFLD动物模型及患者肝脏中ATG3表达升高。
  • 敲低ATG3可减轻脂肪变性,过表达则增加肝细胞脂质负荷。
  • 该保护效应经JNK1-SIRT1-CPT1a通路增强线粒体功能,不依赖自噬。

核心结论

  • ATG3是参与肝脂肪变性发展的新蛋白,抑制肝内ATG3可通过增强线粒体功能改善NAFLD。

研究设计与样本

  • 基于肝内p63基因操作小鼠肝脏的蛋白质组学分析鉴定ATG3为p63下游新靶点。
  • 在NAFLD患者肝样本中评估ATG3,并在人肝细胞系、原代肝细胞及小鼠肝脏中进行ATG3基因操作。

主要发现

  • 与无肝病者相比,NAFLD(脂肪变性及NASH)动物模型和患者肝脏中ATG3表达被诱导。
  • 小鼠与人肝细胞中ATG3基因敲低可改善p63及饮食诱导的脂肪变性,过表达则增加肝细胞脂质负荷。
  • 抑制肝内ATG3通过降低JNK1、增加SIRT1、CPT1a和线粒体功能改善脂肪酸代谢。

关键数值与推荐

  • 肝内敲低SIRT1和CPT1a可削弱ATG3对线粒体活性的影响。
  • 上述效应不依赖自噬作用。

临床怎么用

  • 提示ATG3可作为NAFLD脂肪变性的潜在干预靶点,但尚需临床研究验证。

局限性

  • 原文摘要未报告具体样本量、效应数值及P值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Autophagy-related gene 3 (ATG3) is an enzyme mainly known for its actions in the LC3 lipidation process, which is essential for autophagy. Whether ATG3 plays a role in lipid metabolism or contributes to non-alcoholic fatty liver disease (NAFLD) remains unknown. METHODS: By performing proteomic analysis on livers from mice with genetic manipulation of hepatic p63, a regulator of fatty acid metabolism, we identified ATG3 as a new target downstream of p63. ATG3 was evaluated in liver samples from patients with NAFLD. Further, genetic manipulation of ATG3 was performed in human hepatocyte cell lines, primary hepatocytes and in the livers of mice. RESULTS: ATG3 expression is induced in the liver of animal models and patients with NAFLD (both steatosis and non-alcoholic steatohepatitis) compared with those without liver disease. Moreover, genetic knockdown of ATG3 in mice and human hepatocytes ameliorates p63- and diet-induced steatosis, while its overexpression increases the lipid load in hepatocytes. The inhibition of hepatic ATG3 improves fatty acid metabolism by reducing c-Jun N-terminal protein kinase 1 (JNK1), which increases sirtuin 1 (SIRT1), carnitine palmitoyltransferase 1a (CPT1a), and mitochondrial function. Hepatic knockdown of SIRT1 and CPT1a blunts the effects of ATG3 on mitochondrial activity. Unexpectedly, these effects are independent of an autophagic action. CONCLUSIONS: Collectively, these findings indicate that ATG3 is a novel protein implicated in the development of steatosis. LAY SUMMARY: We show that autophagy-related gene 3 (ATG3) contributes to the progression of non-alcoholic fatty liver disease in humans and mice. Hepatic knockdown of ATG3 ameliorates the development of NAFLD by stimulating mitochondrial function. Thus, ATG3 is an important factor implicated in steatosis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. da Silva Lima N, Fondevila MF, Nóvoa E, et al. Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function. J Hepatol. 2021. PMID: 34555423. doi:10.1016/j.jhep.2021.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。